Physician profile
Jemini Abraham
NPI 1255626461
$2,558.84
in general payments reported to CMS, 2019-2025
32 companies · $320 in 2025
The $320 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.15 · 2020: $340 · 2021: $829 · 2022: $307 · 2023: $454 · 2024: $294 · 2025: $320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $374.89 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $296.06 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $184.09 | 2020-2023 | Mounjaro |
| Abbvie INC. | $137.91 | 2021-2025 | Qulipta, Synthroid, Ubrelvy |
| Merck Sharp & Dohme LLC | $132.56 | 2020-2022 | |
| Glaxosmithkline, LLC. | $129.41 | 2020-2023 | Shingrix, Arexvy |
| Pfizer INC. | $125.09 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $124.14 | 2020-2025 | Farxiga, Airsupra |
| Daiichi Sankyo INC. | $121.02 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $116.00 | 2021 | |
| Amarin Pharma, INC. | $92.91 | 2021 | |
| Amgen INC. | $83.29 | 2020-2025 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $61.31 | 2023-2025 | |
| Eisai INC. | $55.89 | 2020-2021 | |
| Spr Therapeutics, INC | $47.97 | 2024 | Sprint Pns System |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $44.45 | 2023-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $43.49 | 2021-2022 | |
| Medtronic, INC. | $41.55 | 2022-2024 | Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company LTD. | $39.18 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $37.89 | 2025 | Zoryve |
| Dexcom, INC. | $36.47 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $31.26 | 2025 | Vesicare, Veozah |
| Mylan Specialty L.P. | $28.02 | 2020 | |
| Sanofi Pasteur INC. | $24.47 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $24.46 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.15 | 2024 | |
| Idorsia Pharmaceuticals US INC | $19.19 | 2023 | Quviviq |
| Renalytix Ai, INC. | $18.09 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Organon LLC | $18.02 | 2025 | Nexplanon |
| Itamar Medical INC | $17.87 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.99 | 2021 | |
| Nevro Corp. | $12.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jemini Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.